


CICLO SEMINARI Sinergie tra l'Italia e l'Europa nella Lotta contro il cancro
Garantire l'Accesso Universale a Cure Oncologiche e Ridurre le Disuguaglianze

Ridurre le disuguaglianze sociali nel campo dell'oncologia: il progetto EU-CanIneq

19 November 2025, online

Dr Salvatore Vaccarella,
Dr Valentina Lorenzoni,
Dr Serra Kerman, Dr Amine Youcef Ali, IARC
Dr Wilma Nusselder, Erasmus MC

International Agency
for Research on Cancer



Le disuguaglianze socio-economiche nel tumore

- I fattori socioeconomici sono uno dei principali determinanti del cancro tra e all'interno dei Paesi.
- Le disuguaglianze sociali possono influenzare tutte le fasi del percorso del cancro.
 - La mortalità è l'indicatore «ultimo» del cancro e della salute, racchiude l'impatto cumulativo delle disuguaglianze lungo l'intero percorso del cancro.
 - È necessario misurare, mappare, monitorare e confrontare le disuguaglianze socioeconomiche nel cancro tra i diversi Paesi.

The Global Agenda, EU & IARC

- Commission on Social Determinants of Health, 2008
- Rio Declaration on Social Determinants of Health - 2011
- WHA endorsement - 2012
- SDGs - 2015
- WHA Cancer Resolution – 2017
 - Explicit call for monitoring and addressing inequality
- **EU's Beating Cancer Plan**
 - **The Cancer Inequalities Registry**

The IARC Scientific Publication N. 168 on social inequalities and cancer, 2019



- Available evidence, research priorities and global context
- Recommendations to reduce social inequalities in cancer



Contribution of >70
international,
multidisciplinary
experts

European Cancer Inequalities registry

The **European Cancer Inequalities Registry (ECIR)**, a key initiative under *Europe's Beating Cancer Plan*, is tackling disparities head-on by tracking cancer trends and identifying inequalities across EU Member States and regions. This data-driven approach is essential for understanding where the biggest challenges lie and help guide strategic investments at EU, national, and regional levels.



Obiettivo generale del progetto EU-CanIneq

EU-CanIneq (IARC-WHO/Erasmus MC) coordina un quadro di ricerca per sviluppare ed ampliare indicatori rilevanti delle disuguaglianze socioeconomiche nella mortalità per cancro nell'UE

integrato nello European Cancer Inequalities Registry

CANCER MORTALITY BY EDUCATION LEVEL

For 27 EU countries + Norway & Iceland



FOCUS ON THE SOCIOECONOMIC AXIS

One of the most important factors explaining cancer variability within and between countries



- **COLLECTION & LINKAGE OF HIGH-QUALITY DATA**
- **DEVELOPMENT OF METHODS TO PRODUCE ESTIMATES OF CANCER MORTALITY BY EDUCATIONAL LEVEL FILLING TEMPORAL AND GEOGRAPHICAL GAPS**



INTELLIGENCE ON CANCER AND CANCER INEQUALITIES TO IDENTIFY POSSIBLE EXPLANATION FOR OBSERVED INEQUALITIES

Key features of
EU-CanIneq




OVERVIEW OF THE PROJECT




A core of observed, harmonized data, for 16 MS
Based on the linkage of cancer mortality/census

Extrapolation methods developed to fill temporal/geographical gaps



To critically discuss the results and provide possible explanations
Country-specific factsheets

To produce estimates of cancer mortality by educational level for 27 EU countries + Norway and Iceland



DATI E METODI USATI PER LE STIME 2015-2019

ERAINHE dataset: a core of observed, harmonized data about cancer mortality for 16 Member States based on the linkage of cancer mortality/census data

Publicly available data on cancer mortality, population distribution and educational attainment from the **World Health Organization (WHO) mortality database** and **the Eurostat database** and **IARC/GCO database**

	Periods available	Group
Finland	1990-1995; 1995-2000; 2000-2005; 2005-2010; 2011-2015; 2016-2018	A
Sweden	1991-1994; 1995-1999; 2000-2004; 2005-2009; 2010-2014; 2015-2017	A
Denmark	1995-1999; 2000-2004; 2005-2009; 2010-2014; 2015-2019	A
Belgium	1991-1997; 2001-2006; 2006-2011; 2011-2015; 2016-2017	A
France	1990-1995; 1995-1999; 1999-2004; 2004-2007	C
Austria	1991-1992; 2001-2002; 2011-2013; 2013-2014; 2015-2019	A
Italy	2012-2015; 2019; 2020	A
Spain	2002-2006; 2007-2011; 2012-2015; 2016-2019	A
Estonia	2000-2005; 2006-2011; 2012-2015; 2016-2019	A
Lithuania	2001-2005; 2006-2009; 2011-2014; 2015-2019	A
Poland	2001-2003; 2010-2012	B
Czechia	1998-2003	B
Hungary	1988-1991; 1999-2002; 2010-2012; 2015-2019	A
Slovenia	1991-1995; 2002-2006	B
Norway	1990-1995; 1995-2001; 2001-2006; 2006-2009	A
Slovakia	2013-2014; 2015-2019	B

- A. Countries with at least 3 recorded observations over time
- B. Countries with 1 or 2 recorded observations only
- C. Countries with no observations for certain cancer sites (but with information for total cancer)

Methodology
Development of extrapolation methods to fill temporal/geographical gaps

METHODS USED TO OBTAIN ESTIMATES FOR 2015-2019 in the 16 countries with observed data




Three different methods were used depending on the amount of data available:



Relatively large
number of
recorded
observations
over time

A.


Regression models (log-linear when rates are decreasing, otherwise linear) were fitted to the observed **ASMRs on calendar time** and projecting the rates assuming continuation of the past trend until 2015-2019



Only a small
number of
recorded
observations

B.

The average percent change for the **mortality rate** from the GCO-IARC database was **applied to the last observation available** in the ERAINHE dataset



No observations
for certain cancer
types, but with
information on
total cancer
mortality



C.

For each educational group, the share of total cancer mortality for the relevant cancer type was based on the proportion estimated from countries within the same geographical region and applied to total cancer mortality in the last period of observation in that country; thereafter, method B was applied





METHODS USED TO OBTAIN ESTIMATES FOR 2015-2019 in the 13 countries without observed data



<https://platform.who.int/mortality/themes/theme-details/topics/indicator-groups/indicator-group-details/MDB/other-malignant-neoplasms>

https://ec.europa.eu/eurostat/databrowser/view/demo_pjangroup_custom_11728949/default/table?lang=en

https://ec.europa.eu/eurostat/databrowser/view/edat_lfs_9903_custom_10784414/default/table?lang=en

REPORT METODOLOGICO

A **Methodological Report** has been prepared and made available on the ECIR website to provide **details about data and approaches used to produce estimates**, sensitivity analyses performed to evaluate the robustness of the approaches and possible limitations.

The analyses were based on **a core of observed harmonized data on cancer mortality for 16 members states (ERAINHE dataset)**.

The Methodological Report was informed by suggestions & comments of Member State representatives



➤ <https://cancer-inequalities.jrc.ec.europa.eu/country-specific-factsheets#synthesis>

STIME DI MORTALITA' PER TUMORE IN 2015-2019

Estimates of cancer mortality by educational level for 27 EU countries + Norway and Iceland were obtained for **all cancers** and for **six cancer types** (lung, colorectum, stomach, breast, cervical and prostate) and presented as age-standardized mortality rates (**ASMR**) for the age range **40-79 years**.



Schede informative specifiche per Paese

Country-specific factsheets were developed for 27 MS plus Iceland and Norway and delivered **in February 2025**:

- **Based on estimates of cancer mortality rates** produced using the approaches developed.
- Considering available **data on the characteristics of the health system, cancer care, and distribution of risk factors in each country.**
- Before being published, they were circulated among MS representatives and **feedback received were integrated to better**

Schede informative specifiche per Paese

Country-specific factsheets are available on the ECIR- European Cancer Inequalities Registry website:


<https://cancer-inequalities.jrc.ec.europa.eu/country-specific-factsheets>



Le schede-paese forniscono stime della mortalità per cancro e delle disuguaglianze per livello di istruzione (2015–2019), per sesso, **totale tumori e sei sedi specifiche**.

Offrono una **lettura critica** dei risultati alla luce del contesto nazionale (fattori di rischio, sistema sanitario, organizzazione delle cure).

Permettono di **mappare le disuguaglianze tra Paesi**
e supportano lo sviluppo di politiche mirate.



Schede informative specifiche per Paese

Comparing national and European data






Figure 1. Total cancer mortality by sex and education level in Austria

- Compare **country-specific estimates on cancer mortality with the corresponding average European values.**
- Comparison with **other countries in the same geographical area.**
- Understanding **sex differences.**

The European average is obtained as a simple average of data about the 29 countries included in the analysis

Schede informative specifiche per Paese

Assessing inequality gaps across cancer types



Assessment of **the inequality gap** (i.e., the difference between cancer rates among primary educated and cancer rates among tertiary educated).




Figure 2.a. Cancer-specific mortality by sex and education level in Austria: lung




Figure 2.b. Cancer-specific mortality by sex and education level in Austria: colorectum

- Benchmarking with the **European average**.
- Understanding **sex differences**.
- Comparing **different cancer types**.


RISULTATI PRINCIPALI

- In media, nell'UE i tassi di mortalità per cancro risultano **disproporzionatamente elevati tra gli uomini con istruzione primaria**, con 625 decessi per 100.000 rispetto ai 340 decessi per 100.000 tra gli uomini con istruzione terziaria.
- Tra le **donne con istruzione primaria**, i tassi di mortalità per cancro sono stimati in 337 decessi per 100.000, rispetto ai 244 per 100.000 tra quelle con istruzione terziaria.
- Nel complesso, le disuguaglianze educative nella mortalità per cancro risultano più marcate nei **Paesi baltici e dell'Europa orientale**.
- **Tra le donne**, elevati livelli di disuguaglianza socioeconomiche per il cancro sono stati osservati **anche nei Paesi del Nord Europa**.

SPIEGAZIONI POSSIBILI PER LE DISUGUAGLIANZE

Observed socioeconomic inequalities in cancer mortality may derive from the accumulation of inequalities at any stage of the cancer continuum.

- For **cancer types that have a strong and socially patterned risk factor and a relatively bad prognosis (i.e., lung, stomach)**, socioeconomic inequalities in the **accumulation of risk factors** may be more important.
- For **some cancer types (i.e., prostate, cervical)**, inequalities in access to screening, early diagnosis, and treatment may be more relevant.
- For **other cancer types (i.e., colorectal, breast)**, both inequalities in the accumulation of risk factors and in access to screening may play a role.



Risk Factors

Screening

Early Diagnosis

Diagnosis

Treatment

Survival

End of Life Care

L'IMPORTANZA DEL GRADIENTE SOCIALE

- There is a clear **socioeconomic gradient** in cancer mortality across countries and cancer types.
- This means that **cancer inequalities affect everyone**, not only disadvantaged groups.
- It implies that **reducing cancer mortality requires tackling socioeconomic inequalities**.
 - Reducing cancer mortality requires addressing socioeconomic inequalities as a core component of cancer control.

CONCLUSIONI

- L'impatto del cancro non è distribuito in modo equo. La **posizione socioeconomica è chiave**, sia tra che all'interno delle popolazioni.
- Le disuguaglianze socioeconomiche nel cancro sono ampie, **ovunque e per tutti i tumori**.
 - Le persone più svantaggiate pagano il prezzo più alto.
- Le strategie "one-size-fits-all" non riducono le disuguaglianze ma possono addirittura ampliarle.
- Per ridurre l'impatto del cancro è indispensabile affrontare queste disuguaglianze.

TIMELINE



Publication
of the project
factsheet

Launch of
country-specific
factsheets

Acquisition of data

Methodological development to fill
geographical & temporal gaps,
acquisition of additional data

Development of country
specific factsheets

FEB -
APR
2023

MAY - JULY
2023

AUG - OCT
2023

NOV 2023
- JAN 2024

FEB -
APR
2024

MAY - JULY
2024

AUG - OCT
2024

NOV 2024
- JAN 2025

FEB -
APR
2025

MAY - JULY
2025

Year 1

Year 2

Year 3

JUNE 2023,
1st methodological
meeting

Production of
estimates for
countries with
available data in
ERAINHE

MARCH 2024,
2nd methodological
meeting

JUNE 2024,
3rd methodological
meeting

Production of
estimates for 27
MS + Iceland and
Norway

Project extension
until May 2026:

High-Level Session at
IARC 60th Anniversary
Conference

IARC 60th Anniversary International conference

Cancer research into action



19-21 Maggio 2026

- **Send your abstract!**

Thematic focus

Discovery and innovation for cancer prevention
Every breakthrough starts with a question.

Translating research into Public Health action
Science only changes lives when it reaches the people it is meant to serve.

Science-policy interface for global change
Progress happens when evidence drives action.

The screenshot shows the official website for the IARC@60 International Scientific Conference. The header includes the logos of the International Agency for Research on Cancer (IARC) and the World Health Organization (WHO), along with the tagline 'Data Discovery Prevention Knowledge' and a 'Make a donation' button. The main navigation bar lists links for Scientific Advisory Panel Members, Programme, Registration, Abstracts, Prize, Welcome to Lyon, and Partners. The central text announces the 'IARC@60 INTERNATIONAL SCIENTIFIC CONFERENCE: CANCER RESEARCH INTO ACTION' taking place from '19 – 21 May 2026' in 'Lyon, France'. A paragraph describes the conference as a major scientific event to mark IARC's 60th anniversary, held at IARC and la Halle Tony Garnier. Below this is a large image of the IARC building at night. At the bottom, a timeline titled 'SEE YOU IN' shows key dates from October 2025 to May 2026, including registration opening, abstract submission deadlines, and the final conference dates.

International Agency for Research on Cancer
World Health Organization
IARC
Data
Discovery
Prevention
Knowledge
Make a donation

SCIENTIFIC ADVISORY PANEL MEMBERS PROGRAMME REGISTRATION ABSTRACTS PRIZE WELCOME TO LYON PARTNERS

IARC@60 INTERNATIONAL SCIENTIFIC CONFERENCE: CANCER RESEARCH INTO ACTION

19 – 21 May 2026
Lyon, France

To close its **wonderful 60th anniversary year**, IARC will offer you the opportunity to register for a **major scientific conference** that will take place over three days, from **19 to 21 May 2026**. This conference will bring together experts from around the world and will be held at **IARC** and **la Halle Tony Garnier**.

©Kevin BUY

SEE YOU IN

DAYS 182 HOURS 16 MIN 0 SEC 34

8 October 2025 Opening registration
9 October 2025 Opening abstract submission
12 January 2026 Deadline abstract submission
9 February 2026 End of early bird registration
3 March 2026 Notification of acceptance
April 2026 Final programme
19-21 May 2026 IARC@60 Conference